Isomorphic Labs raises $5B to push AI-designed drugs toward human trials
Greenoaks and Sequoia Capital co-led the Series C for Demis Hassabis's Alphabet spinout, six months after its $2.1B Series B. No valuation was disclosed.
By RuntimeWire Staff · Published · Updated

Greenoaks and Sequoia Capital co-led the Series C for Demis Hassabis's Alphabet spinout, six months after its $2.1B Series B. No valuation was disclosed.